Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

110.61 -1.19 (-1.06%)
Streaming Delayed Price Updated: 12:29 PM EDT, Sep 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 160,925
Open 111.97
Bid (Size) 110.61 (100)
Ask (Size) 110.84 (100)
Prev. Close 111.80
Today's Range 109.65 - 112.80
52wk Range 28.66 - 126.38
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
1 Growth Stock Set to Flourishand 2 We Brush Off
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
Topics Supply Chain
News headline image
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property

Performance

YTD
+189.6%
+189.6%
1 Month
-5.6%
-5.6%
3 Month
+33.1%
+33.1%
6 Month
+243.7%
+243.7%
1 Year
+59.1%
+59.1%

More News

Read More
News headline image
Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Mid-Cap Stock for Long-Term Investors and 2 That Underwhelm
Via StockStory
Corcept Therapeutics (NASDAQ:CORT) Surges 21% After Q2 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
Corcept Therapeutics Inc (NASDAQ:CORT) Shows Strong Growth Fundamentals and Technical Breakout Setup ↗
Via Chartmill
News headline image
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Surging Stock to Own for Decades and 2 We Brush Off
Via StockStory
News headline image
3 Cash-Producing Stocks We Steer Clear Of
Via StockStory
News headline image
Corcept Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
Corcept (NASDAQ:CORT) Reports Bullish Q2 CY2026, Stock Jumps 17.4%
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept (CORT) Q2 Earnings: What To Expect
Via StockStory
Topics Artificial Intelligence
News headline image
Why Corcept (CORT) Stock Is Down Today
Via StockStory
News headline image
Spotting Winners: Corcept (NASDAQ:CORT) And Branded Pharmaceuticals Stocks In Q1
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Cash-Heavy Stocks with Questionable Fundamentals
Via StockStory
News headline image
3 High-Flying Stocks We Steer Clear Of
Via StockStory
News headline image
3 Unpopular Stocks We Steer Clear Of
Via StockStory
News headline image
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
From Corcept Therapeutics Incorporated
Via Business Wire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 110.61
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 09/15/26 12:29 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 12.82B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.